Climb Bio, Inc. (CLYM) Form 8-K — Jun 12, 2026
$CLYMForm 8-KItems 1.01, 8.01, 9.01Filed Jun 12, 2026, 8:00 AM ET0001193125-26-269567Original filing
Climb Bio, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on June 12, 2026, allowing the company to sell up to $100 million of its common stock through an at-the-market offering. Jefferies will act as sales agent and receive a commission of up to 3.0% of the gross proceeds from any shares sold. The company simultaneously terminated its previous equity distribution agreement with Oppenheimer & Co.
Key figures
- Gross Proceeds
- 100000000
- Prior Facility Sold
- 0
- Prior Facility Capacity
- 22350000
- Agent Commission Percent
- 3
Price after filing
1 day: 0.0%7 days: +4.9%30 days: +26.7%
Close on the filing date to close N calendar days later (from $10.91). Historical, not a forecast.
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.